OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2021  Archive: 2020 2019 2018 2017
Open Access Research Article
Comparison of Post-mortem 7.0-Tesla Magnetic Resonance Imaging of the Brains of Alzheimer Patients with and without Cerebral Amyloid Angiopathy

Jacques De Reuck *, Florent Auger , Nicolas Durieux , Claude-Alain Maurage , Vincent Deramecourt , Charlotte Cordonnier , Florence Pasquier , Didier Leys , Regis Bordet 

Unitè 1171 “Degenerative and vascular cognitive disorders”, Université de Lille 2, Lille, France

Correspondence: Jacques De Reuck

Academic Editor: James S. Powers

Special Issue: Cerebrovascular Biomarkers in Alzheimer's Disease

Received: September 20, 2020 | Accepted: November 16, 2020 | Published: December 10, 2020

OBM Geriatrics 2020, Volume 4, Issue 4, doi:10.21926/obm.geriatr.2004142

Recommended citation: De Reuck J, Auger F, Durieux N, Maurage CA, Deramecourt V, Cordonnier C, Pasquier F, Leys D, Bordet R. Comparison of Post-mortem 7.0-Tesla Magnetic Resonance Imaging of the Brains of Alzheimer Patients with and without Cerebral Amyloid Angiopathy. OBM Geriatrics 2020;4(4):7; doi:10.21926/obm.geriatr.2004142.

© 2020 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


The influence of cerebral amyloid angiopathy (CAA) in Alzheimer’s disease (AD) remains unexplored. The present post-mortem study investigated possible differences in the degree of hippocampal atrophy (HA) between AD patients with and without CAA using 7.0-tesla magnetic resonance imaging (MRI). Also, the incidence of the hippocampal cortical micro-infarcts (HCoMIs) and hippocampal cortical micro-bleeds (HCoMBs) is compared to those in the neocortex. The examined post-mortem brains included 30 AD-CAA cases and 20 AD without CAA cases. The samples of the hippocampus were evaluated on the most representative coronal section with T2 and T2* MRI sequences. The average degree of HA was determined in both groups. The incidences of HCoMIs and HCoMBs, along with the frequency of CoMIs and CoMBs in the neocortex were compared in both groups: AD-with CAA and AD without CAA cases. No significant differences were observed in the degree of HA and the incidence of hippocampal micro-infarcts (HMIs) and hippocampal micro-bleeds (HMBs) between the AD-CAA and the AD brains in contrast to the higher incidence of these cerebrovascular lesions in the neocortex of AD-CAA brains. The incidence of CoMIs and CoMBs in the neocortex showed similarity to that in the hippocampus of AD patients without CAA. CAA does not influence the degree of HA and the incidence of micro-infarcts (MIs) and micro-bleeds (MBs) in the hippocampus, in contrast to the high contribution of the latter with CAA in the neocortex. The hippocampus seems to be more spared from cerebrovascular involvement than the other parts of the brain.


Post-mortem 7.0-tesla magnetic resonance imaging; Alzheimer’s disease; cerebral amyloid angiopathy; hippocampal atrophy; cortical micro-infarcts; cortical micro-bleeds

1. Introduction

No previous post-mortem study has established a clear association between the presence of β-amyloid and the rates of hippocampal atrophy (HA) in patients with Alzheimer’s disease (AD). In a study, TAR DNA-binding protein 43 (TDP-43) was considered as a potential factor/marker related to increased rates of HA in AD patients [1]. Several studies have established that the rate of HA is associated with both baseline β-amyloid load and accumulation [2]. Also, several arterioles exhibiting significant alpha-smooth muscle actin loss were observed in the hippocampus and the gyrus frontalis medialis in brains of AD patients, which was related to the degree of cerebral amyloid angiopathy (CAA) [3]. Also, capillary CAA and CAA severity were found to be associated with HMIs [4].

Resultantly, divergent opinions concerning the impact of CAA on the degree of HA and the degree of associated cerebrovascular lesions in AD patients have been documented.

The present post-mortem 7.0-tesla magnetic resonance imaging (MRI) study compares the degree of HA between AD brains with associated severe CAA and those without CAA. Also, the incidences of the HMIs and HMBs between AD-CAA and AD brains are compared. Also, their incidence is compared to the frequency of cortical micro-infarcts (CoMIs) and cortical micro-bleeds (CoMBs) in the neocortex.

2. Materials and Methods

Thirty AD-CAA and 20 AD brains in post-mortem were investigated. A previously obtained informed consent of the patients or from the closest family member allowed an autopsy for diagnostic and scientific purposes. The brain tissue samples were acquired from the Lille Neuro-Bank of the Lille University, France that is part of the “Centre de Ressources Biologiques” and acts as an institutional review board (IRB).

The neuropathological examination was conducted according to a standard procedure [5]. The Braak criteria were employed to determine the severity of the tau pathology. Only grade V and VI stages were retained as a definitive diagnosis of AD [6]. The presence of various degrees of CAA was made according to the criteria of a consensus protocol with gradations from 0 to 3 on examining cortical samples of the frontal, temporal, parietal, and occipital cortex with β-amyloid staining [7].

A 7.0-Tesla MRI Bruker BioSpin SA (BioSpin GmbH, Ettlingen, Germany) was used with an issuer-receiver cylinder coil with an inner diameter of 72 mm. The same was used in an earlier study [8]. Three to six coronal sections of a cerebral hemisphere were submitted to SPIN ECHO T2 and T2* MRI sequences before the brain sampling for the histological examination. The hippocampus was evaluated on the most representative section. The degree of in vivo HA was determined using Scheltens criteria [9,10]. This criterion was applied to post-mortem 7.0-tesla MRI [11]. Also, the incidence of HMIs and HMBs were evaluated for cortical hemispheric CoMIs and CoMBs [12].

Uniform comparisons of unpaired groups were made with Fisher’s exact test for categorical data. The non-parametric Mann-Whitney U-test was employed to compare continuous variables. The significance level, two-tailed, was set at ≤ 0.01 for significant and ≤ 0.001 for highly significant. p-Values set at ≤ 0.05 and more than > 0.01 were considered as marginally significant.

3. Results

The mean ages of the patients with AD-CAA and with AD were almost similar and were 77 (63-84) years, and 78 (65-83) years, respectively. No gender differences were observed with an incidence of 41% in the AD-CAA brains and 40% in the AD ones. A territorial infarct was noticed in five (25%) AD-CAA brains and in one (3%) patient with AD without CAA. Lobar hematomas were found in eight (40%) AD-CAA brains and were restricted to one (3%) with only the AD.

No differences concerning the degree of HA and the incidence of HMIs and HMBs between the AD and the AD-CAA brains were observed. A significant difference in the occurrence of CoMIs and CoMBs was found in the neocortex with a considerable increase in the AD-CAA brains (p ≤ 0.001), compared to the similar rate of HMIs and HMBs in the AD and AD-CAA ones (Figure 1 and Figure 2). The occurrence of HMIs and HMBs was more or less similar as in the neocortex of “pure” AD patients (Table 1).

Click to view original image

Figure 1 T2 and T2* sequences of a coronal section of a cerebral hemisphere in a patient with AD and CAA. Note in addition to the severe dilation of the temporal horn and the small hippocampus (*), a cortical micro-infarct (white arrow) on the T2 sequence and two cortical micro-bleeds (black arrow) on the T2*.

Click to view original image

Figure 2 T2 and T2* sequences of a coronal section of a cerebral hemisphere in a patient with Alzheimer’s dementia without cerebral amyloid angiopathy. There is severe dilation of the temporal horn with a small remaining hippocampus (*).

Table 1 Comparison of the degree of hippocampal lesions in Alzheimer’s disease (AD) with and without cerebral amyloid angiopathy (CAA) and the incidence of cerebrovascular lesions in the neocortex.

4. Discussion

There is a good correlation between the visual MRI quantification of medial temporal lobe atrophy and HA compared to the classical neuropathological evaluation [13].

The present study revealed no difference in the degree of HA and the frequency of HMIs and HMBs between AD-CAA brains and AD brains. This is in contrast with the high incidence of neocortical CoMIs and CoMBs in AD-CAA brains compared to “pure” AD ones (p ≤ 0.001). In the present post-mortem study, no association between β-amyloid or tau proteins and rates of HA was established in AD brains.

HA is not specific to AD with or without CAA but is also observed in frontotemporal dementia [14,15]. The higher incidence of neocortical CoMiIs and CoMiBs has already been described in some earlier studies [16,17].

Both AD-CAA and AD patients were of similarly advanced age when they died. The disease duration was not evaluated, as the early clinical onset of AD is not always clear. During the aging process, only increased severity of white matter changes and the incidence of CoMBs are observed. CoMIs showed no increase with advancing age [18].

Some previous studies have shown a higher incidence of CoMIs and CoMiBs in the neocortex of patients with AD-CAA compared to AD ones [12,19,20]. Also, in CAA patients without AD features, the incidence of these lesions is even higher than in AD-CAA ones [21].

5. Conclusion

It can be concluded that CAA has no significant influence on the degree of HA and the associated small cerebrovascular lesions in contrast to those in the hemispheric neocortex. Further studies on large populations are suggested to establish a clear link and thereby take proper diagnostic and preventive interventions to reduce morbidities from the deadly disease of CAA.

Author Contributions

Jacques De Reuck has designed the study. Together with Florent Auger and Nicolas Durieux he performed the MRI examinations. Claude-Alain Maurage and Vincent Deramecourt performed the macroscopic and histological examinations of the brains. Charlotte Cordonnier, Florence Pasquier, Didier Leys and Regis Bordet were responsible for clinical evaluation during life.

Competing Interests

The authors have declared that no competing interests exist.


  1. Joseph KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: A longitudinal retrospective study. Lancet Neurol. 2017; 16: 917-924. [CrossRef]
  2. Andrews KA, Frost C, Modat M, Cardaso MJ, Rowe CC, Villemagne V, et al. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiol Aging. 2016; 39: 99-107. [CrossRef]
  3. Merlini M, Wanner D, Nitsch RM. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer’s disease-related microvasular cerebral amyloid angiopathy. Acta Neuropathol. 2016; 131: 737-752. [CrossRef]
  4. Hecht M, Krämer LM, von Arnim CA, Otto M, Thal DR. Capillary cerebral amyloid angiopathy in Alzheimer’s disease association with allocortex: Hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 2018; 135: 681-694. [CrossRef]
  5. De Reuck J. Histopathological stai nings and definitions of vascular disruptions in the elderly brain. Exp Geront. 2012; 47: 834-837. [CrossRef]
  6. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-259. [CrossRef]
  7. Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, et al. Development, appraisal, validation and implementation of a consensus protocol for assessment of cerebral amyloidal angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014; 3: 19-32.
  8. De Reuck J, Auger F, Cordonnier C, Deramecourt V, Durieux N, Pasquier F, et al. Comparison of 7.0-T T2*-magnetic resonance imaging of cerebral bleeds in post-mortem brain sections of Alzheimer patients with their neuropathological correlates. Cerebrovasc Dis. 2011; 31: 511-517. [CrossRef]
  9. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal aging: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992; 55: 967-972. [CrossRef]
  10. Wahlund L, Julin P, Johansson S, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging: A comparative study. J Neurol Neurosurg Psychiatry. 2000; 69: 630-635. [CrossRef]
  11. Blanken AE, Hurtz S, Zarow C, Biado K, Honarpisheh H, Somme J, et al. Association between hippocampal morphometry and neuropathological markers of Alzheimer’s disease using 7 T MRI. Neuroimage Clin. 2017; 15: 56-61. [CrossRef]
  12. De Reuck J, Auger F, Durieux N, Deramecourt V, Maurage CA, Pasquier F, et al. Cerebrovascular lesions during normal aging: A neuropathological study with 7.0-tesla magnetic resonance imaging. EC Neurology. 2018; 10: 229-235.
  13. Boutet C, Chupin M, Colliot O, Sarazin M, Mutlu G, Drier A, et al. Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer’s disease? Neuroradiology. 2012; 54: 1321-1330. [CrossRef]
  14. de Souza LC, Chupin M, Bertoux M, Lehéricy S, Dubois B, Lamari F, et al. Is hippocampal volume a good marker to differentiate Alzheimer’s disease from frontotemporal dementia? J Alzheimers Dis. 2013; 36: 57-66. [CrossRef]
  15. Hornberger M, Wong S, Tan R, Irish M, Piguet O, Kril J, et al. In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer’s disease. Brain. 2012; 135: 3015-3025. [CrossRef]
  16. De Reuck J, Auger F, Durieux N, Maurage CA, Deramecourt V, Cordonnier C, et al. Post-Mortem 7.0-tesla magnetic resonance imaging of the hippocampus during normal aging and in neurodegenerative dementias. SunText Rev Neurosci Psychol. 2020; 1: 108-113.
  17. De Reuck J, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D, et al. Post-mortem 7.0-tesla magnetic resonance study of cortical micro-infarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. J Neurol Sci. 2014; 346: 85-89. [CrossRef]
  18. De Reuck J, Cordonnier C, Deramecourt V, Auger F, Durieux N, Bordet R, et al. Microbleeds in postmortem brains of patients with Alzheimer disease. A T2*-weighted gradient-echo 7.0 T magnetic resonance imaging study. Alzheimer Dis Assoc Disord. 2013; 27: 162-167. [CrossRef]
  19. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg SM. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology. 2009; 72: 1230-1235. [CrossRef]
  20. van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb AG, Blauw GJ, et al. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology. 2014; 270: 205-211. [CrossRef]
  21. De Reuck J, Cordonnier C, Auger F, Durieux N, Maurage CA, Deramecourt V, et al. Cerebrovascular lesions in cerebral amyloid angiopathy with and without Alzheimer’s disease: A neuropathological study with post-mortem 7.0-t magnetic resonance imaging. EC Neurology. 2018; 10: 954-960.
Download PDF
0 0